THAC is a privately-owned small, yet highly innovative, biopharmaceutical company which aims to become a game changer in patient care and healthy aging by targeting age-related diseases and in particular Alzheimer’s disease and Type 2 Mellitus Diabetic Neuropathy, major unmet medical needs.